Rotaver

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rotaver

Quick Facts

Property Description
Active ingredient Betahistine (Betahistine dihydrochloride)
Form Tablet (Oral administration)
Pharmacological class Antivertigo preparation (Histamine analogue)
General purpose Relief of vertigo and dizziness symptoms
Origin Synthetic (Monocomponent product)

Rotaver: Defining the Antivertigo Preparation

Rotaver is a prescription-only pharmaceutical product whose active substance is Betahistine, classified as an Antivertigo preparation. This medication is clinically recognized for the management of chronic balance disorders stemming from the inner ear, such as those that cause persistent feelings of unsteadiness or spinning. The drug is structurally defined as a histamine analogue, a compound chemically synthesized to resemble histamine, a substance naturally present in the body.

Composition and Origin: The Betahistine Tablet

The active ingredient in Rotaver is Betahistine dihydrochloride, which is formulated for oral administration in a solid tablet dosage form. Betahistine is a synthetic aminoalkylpyridine compound, not derived from a natural source. Rotaver is characterized as a single monocomponent product, relying exclusively on the Betahistine substance for its therapeutic effects. This synthetic composition allows for a consistent and controlled therapeutic profile.

General Benefit: Stabilizing the Inner Ear Balance System

The general purpose of Rotaver is to relieve symptoms of vertigo and dizziness by stabilizing the function of the vestibular system. A typical use scenario involves helping patients mitigate the frequency and intensity of recurrent episodes of dizziness that disrupt daily activities. This benefit is linked to the drug's mechanism, which improves blood flow within the inner ear structures and facilitates the brain’s natural process of vestibular compensation. This targeted action helps regulate sensory information, a key differentiator from general motion sickness remedies.

Regulatory References

  1. WHO
  2. EMA
  3. Public Assessment Report for Betahistine Amarox

What side effects are possible with Rotaver?

Possible Side Effects and Safety Information

The safety profile of Rotaver (Betahistine dihydrochloride) is structured by official regulatory documents, classifying possible adverse reactions by their system-organ class and frequency of occurrence.


Adverse Reactions Classified by Frequency

Adverse effects listed in official labeling are categorized based on data from clinical trials and post-marketing reports:

Classification Examples of Documented Adverse Reactions
Common (Affects 1 to 10 users in 100) Headache (Nervous System), Nausea, Dyspepsia (Gastrointestinal Disorders)
Frequency Not Known (Post-marketing reports only) Hypersensitivity Reactions (e.g., Anaphylaxis), Cutaneous Reactions (e.g., Urticaria, Angioneurotic oedema), Mild Gastric Complaints (e.g., Vomiting, Abdominal pain)

Serious adverse reactions documented in post-marketing reports include severe hypersensitivity reactions, such as anaphylaxis.


Special Safety Considerations

The regulatory safety profile notes specific conditions or populations requiring caution, as defined in official prescribing information:

  • Existing Conditions: Caution is advised for individuals with bronchial asthma, a history of peptic ulceration, and those with severe hypotension.
  • Allergic Risk: Patients with pre-existing allergic conditions (e.g., rashes, allergic rhinitis) should be monitored.
  • Pediatric Use: The safety and efficacy of the medication have not been established in children under 18 years of age.

Furthermore, official documentation indicates a high-level safety note regarding potential interactions, specifically with H1 antagonist antihistamines (due to mutual attenuation of effect) and Monoamine Oxidase (MAO) inhibitors.

Overdose and Emergency Response

Overdose and when to seek help

The following information on Rotaver (Betahistine) overdose is based strictly on documentation provided by governmental regulatory bodies.

Documented Manifestations of Overdose

Official prescribing information notes that overdose symptoms typically range from mild to moderate, often involving the gastrointestinal and nervous systems. These documented signs include Nausea, Somnolence (drowsiness), and Abdominal Pain.

Classification Symptom or Outcome
Mild to Moderate Nausea, Somnolence, Abdominal Pain
Serious Complications Convulsion, Pulmonary Complications, Cardiac Complications

Seeking Urgent Medical Attention

The most severe manifestations, such as Convulsion, Pulmonary Complications, or Cardiac Complications, are primarily reported following cases of intentional overdose or when Betahistine was ingested in combination with other drugs. Immediate medical attention must be sought if any of these serious complications occur.

There is no specific antidote documented for Rotaver overdose. Management protocols established by regulatory authorities require standard supportive measures and symptomatic treatment to manage the manifestations and monitor the patient for any signs of deterioration.

Therapeutic Uses of Rotaver

What Rotaver Treats: Main Uses and Benefits

Rotaver is used to help provide protection against Rotavirus Gastroenteritis (a severe form of stomach flu) in infants and young children, a condition characterized by symptoms related to systemic imbalance and symptoms related to heightened physiological activity. The vaccine is generally considered a relevant tool to help protect against this disease, which is a common cause of illness presenting with systemic or localized discomfort in this age group.

It is applied across conditions presenting with acute episodes, and may help reduce the risk of severe outcomes, such as severe dehydration and the need for emergency room visits or hospitalization. This measure supports the child during episodes of heightened discomfort by easing the potential impact of an infection.

Indications Summary: Rotaver is commonly used for the prevention of rotavirus illness, contributing to the support process for the risk of profound fluid loss, and general well-being during infancy.

“By preventing severe illness, it contributes to improved day-to-day comfort during the early months.”

Quick Fact: Relief for Symptoms that Create Noticeable Physiological Strain

Rotaver is relevant for healthy infants, and may help lessen the impact of this highly contagious virus. By preventing severe illness, it assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Rotaver?

This section outlines the population eligibility and non-eligibility for Rotaver (Betahistine), based strictly on official regulatory labeling.


Eligibility Scope

Classification Population Group Regulatory Status
Use Allowed Adults (18 years and over) and Older Adults Use is permitted; no dose adjustment is necessary for the elderly.
Contraindicated Patients with Phaeochromocytoma Use is prohibited (Absolute Contraindication).
Contraindicated Patients with known Hypersensitivity Use is prohibited (Absolute Contraindication).
Contraindicated Patients with Active Peptic Ulcer or History Use is prohibited (Contraindication in some regions).
Not Recommended Children and Adolescents (Below 18 years) Use is not recommended; safety and efficacy are not established.
Not Recommended Lactating/Nursing Women Use is not recommended; risk to the infant is unknown.
Caution Required Patients with Bronchial Asthma Requires careful monitoring during treatment.
Caution Required Patients with Severe Hypotension Requires careful monitoring during treatment.

Physiological and Condition-Based Limitations

Pregnancy: Use should be avoided unless clearly necessary, as the potential risk for humans is unknown. Renal and Hepatic Impairment: Use is acceptable for patients with impaired kidney or liver function; no dose adjustment is necessary based on post-marketing experience. The official regulatory status formally establishes use for adults, while imposing constraints on use based on co-existing medical conditions and developmental age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rotaver, whose active substance is Betahistine, has officially documented interaction patterns primarily involving medicinal products that affect the histamine system and those that influence its metabolism. This information is based on formal regulatory documentation and clinical pharmacokinetic data detailing interaction constraints.


Pharmacodynamic and Restricted Combinations

The co-administration of Rotaver with Antihistamines ( H1 antagonists) should not be used. This strong restriction is due to the potential for mutual attenuation of the effect of both medicines, a theoretical but formally noted risk in regulatory product labeling.


Metabolic Interactions and Exposure

Monoamino-oxidase (MAO) inhibitors, including MAO-B selective agents such as Selegiline, are documented to warrant caution when used concurrently. In vitro data suggests that MAO inhibitors may inhibit the metabolism of Betahistine, resulting in the potential for increased plasma levels of the active ingredient. Regulatory data also formally excludes a common interaction pathway by stating that Rotaver is not expected to cause in vivo inhibition of major Cytochrome P450 enzymes.


Interaction with Food Intake

Regulatory pharmacokinetic studies indicate that administration of Rotaver with food intake affects the drug's absorption rate. Specifically, food intake leads to a lower maximum plasma concentration ( C max). However, the total extent of absorption (AUC) remains similar, confirming that the overall drug exposure is not reduced. No mandatory timing separation rules are documented based on food.

Mechanism of Action

Rotaver primarily modulates the histaminergic system through a dual mechanistic action. Centrally, the drug acts as an antagonist at the Histamine mathbfH3 receptors (H₃R), removing the neural inhibitory function on presynaptic histaminergic neurons. This targeted mechanism increases the concentration of endogenous histamine in the brainstem, particularly within the vestibular nuclei, thereby accelerating the neuroplastic process of vestibular compensation.

Peripherally, a secondary, complementary mechanism involves a weak partial agonism at the Histamine mathbfH1 receptors (H₁R) located on the microvessels of the inner ear. This interaction causes local vasodilation and an increase in blood flow to the labyrinth and cochlea. The resulting increase in local perfusion contributes to modulating the fluid dynamics and physiological environment of the balance organs.

The combined central and peripheral action directly influences the electrical excitability of vestibular neurons. By modulating overactive signaling and facilitating the central mechanism for compensation of peripheral deficits, the drug mechanism influences the fidelity of spatial orientation information transfer.

Dosage and Administration Information

Rotaver is officially utilized as a time-sensitive, multi-dose regimen administered exclusively via the oral route to infants. Under no circumstances is the product to be injected, as the liquid is a ready-to-use suspension intended for delivery directly into the infant's mouth.

The usage protocol is strictly governed by age. The first dose of the series must be given starting at 6 weeks of age, with subsequent doses requiring a minimum interval of four weeks. The complete course must adhere to a defined time window, typically being finalized by the age of 24 weeks for two-dose regimens or 32 weeks for three-dose regimens.

Each dose involves the administration of a standardized volume, which is either 1.5 mL or 2.0 mL, depending on the specific product formulation being used. There is no requirement to adjust feeding practices, including breastfeeding, immediately before or after the administration of the dose. However, proper administration may be dependent on the patient’s condition: if an infant is experiencing acute symptoms like diarrhea or vomiting at the time of the scheduled visit, the dose is generally postponed. If the infant regurgitates the dose, a single replacement may be considered at the same visit to ensure the correct procedural steps are followed.

Recent Clinical Evidence

Research evidence / Overview of studies for Rotaver

Evidence for Use in Rotavirus Gastroenteritis Prevention

This section summarizes the research that has examined the product's data in the prevention of severe rotavirus gastroenteritis in infants and young children. Research for this purpose primarily involves large, multi-center Randomized Controlled Trials (RCTs) and ongoing post-licensure observational studies. These studies were evaluated in populations of healthy infants to monitor outcomes related to physical discomfort and outcomes related to systemic or functional imbalance caused by the virus.

The major trials monitored outcomes such as the incidence of severe rotavirus gastroenteritis. Research also explored whether the product was associated with the number of hospitalizations and emergency room visits linked to the illness. Findings from these large studies describe patterns observed in the studies where rates of severe disease in the group that received the product were evaluated against the control group.

Evidence for Use in Vertigo and Dizziness Symptoms

The active ingredient in Rotaver, Betahistine, was studied for its use in conditions characterized by fluctuating or episodic manifestations of inner ear imbalance, such as Meniere's disease. The available evidence includes older, typically small-to-moderate-sized RCTs, as well as subsequent systematic reviews and meta-analyses that summarize those findings. The trials used in research exploring how symptoms change over time primarily focused on outcomes related to physical discomfort, such as measuring patient-reported outcomes describing perceived discomfort and the frequency, intensity, and duration of vertigo attacks.

Across the available evidence, some studies report how symptoms evolved in the observed populations, suggesting that patterns of vertigo attack frequency may be different in some patients compared to an inactive treatment (placebo). However, scientific reviews indicate that findings were mixed regarding changes in other symptom axes, such as measurements of functional status.


Understanding Evidence Gaps and Limitations

The evidence quality varies across studies, with many older trials for the vertigo use having been small or methodologically limited. The certainty remains low for some of the findings evaluated in studies that compared the product to an inactive treatment. The scientific literature notes that study findings for rotavirus prevention were observed in all settings, but data show patterns related to observed effect that may vary between high-income and low-income countries.

Frequently Asked Questions (FAQ)

Common questions about Rotaver (FAQ)


Q: Are there any specific foods or drinks to avoid while taking Rotaver?

Official product information states that Rotaver can be taken with or without food. Although food intake may affect how quickly the medicine reaches its highest concentration in the blood, the overall amount absorbed remains similar.

Official documents also confirm that consumption of alcohol is generally permitted while taking this medicine.


Q: Are there any common over-the-counter medicines that interact with Rotaver?

Regulatory product labeling notes a restriction against the concurrent use of certain antihistamines (H1 antagonists), which are commonly found in over-the-counter allergy and cold medicines.

This restriction is formally noted based on the theoretical potential for the mutual attenuation of effects between both medications.


Q: Is it normal to feel slightly dizzy when first starting Rotaver?

Official documentation lists dizziness as an infrequent adverse effect of Rotaver. Since the medicine is used to relieve dizziness, it can sometimes be difficult to distinguish between the symptoms of the condition being treated and potential side effects.

Information found in regulatory documents emphasizes that all persistent or worsening symptoms should be brought to the attention of a healthcare professional.


Q: What is the safety rating or classification of Rotaver?

Rotaver is officially categorized as a prescription-only pharmaceutical product. It is classified by the World Health Organization (WHO) as an Antivertigo preparation—a type of medicine used for conditions related to balance.

This classification helps define its general therapeutic use.


Q: Is the long-term use of Rotaver generally studied?

Research studies have examined the product's use for managing chronic inner ear conditions that cause fluctuating symptoms. Regulatory experience indicates that the medicine has generally been well tolerated and is sometimes used in the long-term management of certain conditions.


Q: Is Rotaver used to prevent diseases, or only to treat them?

Rotaver is described in official labeling for the relief and management of symptoms associated with chronic balance disorders, such as vertigo and dizziness. Its general purpose is to stabilize the function of the vestibular system, which is consistent with a treatment or management role rather than a preventive one.


Q: How quickly should someone expect Rotaver to start working?

Pharmacokinetic data from regulatory documents indicates that the peak concentration of Rotaver in the bloodstream is typically reached about one hour after it is administered while fasting.

This measurement reflects when the active ingredient is most abundant in the system.


Q: If I miss a dose of Rotaver, what should I generally do?

Official regulatory instructions provide general guidance for a missed dose. The regulatory guidance describes taking the dose as soon as it is remembered, unless the time is very near the next scheduled administration.

Official information explicitly states that a double dose should not be taken to make up for the one that was missed.


Q: Is it true that Rotaver can cause fatigue?

Official regulatory documents indicate that Rotaver does not list fatigue as a common side effect. However, tiredness or general malaise is reported in regulatory post-marketing data as a rare adverse effect experienced by some users.


Q: How long does Rotaver typically stay in the body after stopping its use?

Regulatory pharmacokinetic data describes the elimination of the active substance. The mean plasma elimination half-life is approximately 3 to 4 hours, which means it takes that amount of time for half the substance to be cleared from the plasma.

The overall process of excretion via the urine is typically considered virtually complete within 24 hours.


Q: Does taking Rotaver mean I have to avoid driving?

Regulatory documents explicitly state that there is no indication that Rotaver affects the ability to drive or use machinery. However, the condition Rotaver treats, such as vertigo, can inherently cause dizziness.

Regulatory product information notes that caution is advised, as the underlying condition itself may pose a risk to the ability to operate machinery safely.


Q: Is Rotaver habit-forming or addictive?

According to the official consumer medicine information (CMI), Rotaver is not classified as a controlled substance. Regulatory documents explicitly state that there is no evidence that the active ingredient, Betahistine, is habit-forming or leads to addiction.


Q: Can Rotaver change the results of certain lab tests?

Official regulatory documentation notes that there is currently no data available regarding the medicine's potential to alter the results of laboratory tests. This means that effects on diagnostic test results have not been formally documented in the regulatory information.


Q: How long can I generally expect to take Rotaver?

Rotaver is typically used for the management of chronic balance disorders where symptoms fluctuate over time. The medicine is sometimes prescribed for continuous, long-term use for symptom management, depending on the professional assessment of the chronic condition.


Q: Does Rotaver interact with herbal supplements like St. John's Wort?

Regulatory guidance often highlights that there is insufficient data to confirm whether herbal remedies or complementary medicines, such as St. John's Wort, are safe to take with Rotaver.

Official documents refer individuals to a healthcare professional for specific information on combining this medicine with supplements.


Q: Are there restrictions on caffeine consumption while on Rotaver?

Official regulatory documentation does not specify mandatory restrictions on caffeine consumption while taking Rotaver. However, some regulatory sources note that individuals managing the symptoms Rotaver treats may report a benefit from reducing their intake of caffeine.


Q: Can Rotaver cause weight changes?

When reviewing the established safety profile, official regulatory documents do not list weight changes, such as weight gain or weight loss, as a reported common, uncommon, or rare side effect of Rotaver.


Q: Are there official warnings about Rotaver and alcohol consumption?

Official regulatory documentation indicates that alcohol consumption is permitted while taking Rotaver. However, for individuals with certain balance disorders, some official sources suggest that reducing alcohol intake may contribute to symptom improvement.


Q: Why is Rotaver sometimes mentioned with a specific diet?

Official regulatory information notes that individuals with conditions like Meniere's disease, which Rotaver is used to manage, sometimes report that their symptoms improve when adhering to a low-salt diet.

This connection relates to managing the underlying condition, not a mandatory interaction with the drug.


Q: Can Rotaver cause issues with sleep?

Regulatory consumer medicine information (CMI) for Rotaver lists difficulty sleeping, sometimes described as insomnia, as a less serious side effect. This type of adverse reaction is reported by some users but is not listed as a common occurrence.

How should Rotaver be stored and disposed of?

How to Store and Dispose of Rotaver?

Rotaver (Betahistine tablets) must be stored and disposed of according to official regulatory guidelines to maintain its stability and ensure environmental safety.

Storage Requirements

  • Temperature: Storage is typically required at ambient temperatures, with some regulatory documents specifying temperatures not exceeding 30 C.
  • Protection: The medicine must be stored in its original pack or container to protect it from moisture. The product must not be used after the expiry date printed on the packaging.
  • Child Safety: Rotaver must be stored out of the sight and reach of children, as mandated for all prescription medicines.

Disposal Instructions

  • Environmental Rule: Do not throw away any medicines via wastewater or household waste due to environmental protection mandates.
  • Official Process: The correct disposal procedure is to ask your pharmacist how to dispose of medicines you no longer use, ensuring the product is handled as pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rotaver found in:

A-Z Index: